Hemophilia Spin-Off Hemophilia Spin-Off (Details Textual) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Feb. 01, 2017
Assets and Liabilities Distributed to Bioverativ [Line Items]
Other revenues	$ 179.6	$ 48.8	$ 41.6	$ 90.0	$ 50.9	$ 98.6	$ 79.0	$ 87.9	$ 360.0	$ 316.4	$ 236.1
Cost of sales									1,630.0	1,478.7	1,240.4
Product, net	$ 2,712.4	$ 2,622.5	$ 2,639.7	$ 2,380.1	$ 2,502.9	$ 2,539.6	$ 2,466.0	$ 2,309.4	10,354.7	9,817.9	9,188.5
Bioverativ
Assets and Liabilities Distributed to Bioverativ [Line Items]
Term of Bioverativ Transaction Services Agreement				12 months
Term of Bioverativ Manufacturing and Supply Agreement				5 years
Cash												$ 302.7
Other revenues									64.8
Cost of sales									15.1
Hemophilia Products
Assets and Liabilities Distributed to Bioverativ [Line Items]
Product, net									$ 74.4	$ 846.9	$ 554.2